UnitedHealth faces IRS fight over foreign subsidiary transactions and potential tax bill

UnitedHealth Enters Transfer Pricing Clash With IRS Over Overseas Subsidiary Deals

Theindiapostdaily.com – The healthcare conglomerate UnitedHealth Group has formally pushed back against proposed Internal Revenue Service adjustments that, if sustained, would inflate the firm’s taxable income tied to dealings with an overseas affiliate. The confrontation places the company squarely inside the ongoing wave of high-stakes transfer pricing battles pitting American multinationals against the federal tax authority.

What the Dispute Covers

Company filings, as referenced by Fortune, indicate the IRS examination spans UnitedHealth’s tax years from 2017 through 2020. The agency’s proposed changes would push taxable income higher in each of those years, and the IRS retains the option to seek comparable modifications for later periods. UnitedHealth has declined to name the foreign entity at issue, describe the specific transactions under review, or attach a dollar figure to the additional tax the agency is pursuing.

The Transfer Pricing Mechanism

At the heart of the matter sits transfer pricing — the framework by which multinationals set internal prices for goods, services, or intellectual property exchanged between affiliated units in separate countries. Those internal prices shape where profits land and, by extension, where tax revenue is collected. Section 482 of the Internal Revenue Code empowers the IRS to rewrite taxable income whenever it determines that intercompany transactions were not priced at arm’s length.

UnitedHealth’s Stance

In an August filing, the company stated that its tax positions are adequately supported and that it intends to “vigorously contest” the agency’s proposed adjustments. A UnitedHealth Group spokesperson added:

“The company has previously disclosed the IRS examination and related tax matters in its public filings and believes its tax positions are properly supported.”

The spokesperson noted the matters “remain subject to further review and discussions.”

Importantly, the IRS notices at play here are proposed adjustments rather than final assessments or penalties. Should the examination fail to produce a resolution, UnitedHealth retains the right to pursue administrative appeals and, ultimately, litigate the issue in court.

Financial Exposure Remains Uncertain

The magnitude of any eventual liability is not yet public. UnitedHealth reported $5.6 billion in gross unrecognised tax benefits as of the close of 2025, a jump from $4.1 billion a year earlier, though the company cautioned that that aggregate figure encompasses every uncertain tax position on its books. A spokesperson clarified that the $5.6 billion number “should not be interpreted as the amount associated with the NOPAs.”

A Pattern of Escalating Scrutiny

The UnitedHealth confrontation arrives amid years of intensified IRS attention on how American multinationals split profits between domestic operations and foreign subsidiaries. Comparable disputes have involved Coca-Cola, Meta, and Medtronic, with some stretching across multiple years and billions of dollars.

Coca-Cola’s transfer pricing litigation, for instance, could ultimately encompass roughly $20 billion in combined tax and interest. Meta is contesting an IRS claim seeking $15.89 billion in additional tax, interest, and penalties covering 2017 through 2019. In UnitedHealth’s case, neither the company nor the agency has revealed how much money could ultimately be at stake, leaving the dispute unresolved and its financial ceiling unknown.